01 March 2014
: Case report 
Interstitial granulomatous dermatitis successfully treated with etanercept
Unknown etiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy
Zavier Shawkat AhmedBCDEFG, Sabaa JoadACDG, Manpreet SinghAFG, Sabiha S. BandagiADFDOI: 10.12659/AJCR.890074
Am J Case Rep 2014; 15:94-96
Abstract
BACKGROUND: Interstitial granulomatous disease (IGD) is a rare skin condition that presents with erythematous and violaceous plaques, and may be associated with pruritus and pain. The cause remains unknown, but is often associated with autoimmune disease and drug-related adverse effects. It is diagnosed via biopsy, and the treatment remains unclear.
CASE REPORT: We report a case of biopsy-proven IGD associated with rheumatoid arthritis that was treated successfully with etanercept therapy.
CONCLUSIONS: We emphasize that anti-TNF antibodies may be clinically effective for the treatment of IGD.
Keywords: etanercept, rheumatoid arthritis, Interstitial Granulomatous Dermatitis (IGD)
In Press
26 Jan 2023 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.938169
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939026
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938982
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938850
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
06 Dec 2021 : Case report 
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report 
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399